| 摘要 |
Increasing evidences have expanded the concept that inflammation is a critical
component of tumor progression and therapeutic resistance in most types of
malignancy. The mediators and cellular effectors of inflammation are important
constituents of tumor microenvironment. ‘Smoldering’ inflammation in the tumor
microenvironment induces many tumor-promoting effects, including fostering of cell
proliferation and survival, promotion of angiogenesis, tumor invasion/metastasis,
and evasion of host immunosurveillance. The molecular pathways of the cancerrelated
inflammation are now being unraveled, resulting in the identification of new
target molecules that could lead to improved diagnosis and treatment.
The current clinicopathological staging system for esophageal squamous cell
carcinoma (ESCC) is inadequate for predicting the therapeutic response and
prognosis. It is believed that multiple intrinsic factors in making the difference of
therapeutic responses or outcomes exist. An association of chronic inflammation in
the esophagus with tumor initiation and promotion indicates that an understanding
on the clinical implications and the pathophysiological regulation of the
inflammation-related biomarkers is quite important in prognostic prediction and
improvement of therapeutic outcomes, or innovative therapeutic strategy, for ESCC
patients. In an attempt to broaden our knowledge, we have, in this review article,
also summarized the common mechanisms associated with inflammation-related
biomarkers identified in ESCC. |
